Connecting the Dots: FGF21 as a Potential Link between Obesity and Cardiovascular Health in Acute Coronary Syndrome Patients

被引:0
作者
Negroiu, Cristina Elena [1 ,2 ]
Riza, Anca-Lelia [3 ,4 ]
Streata, Ioana [3 ,4 ]
Tudorascu, Iulia [1 ]
Bezna, Cristina Maria [1 ,5 ]
Ungureanu, Adrian Ionut [2 ,5 ]
Danoiu, Suzana [1 ]
机构
[1] Univ Med & Pharm Craiova, Dept Pathophysiol, Craiova 200642, Romania
[2] Univ Med & Pharm Craiova, Doctoral Sch, Craiova 200349, Romania
[3] Univ Med & Pharm Craiova, Lab Human Genom, Craiova 200638, Romania
[4] Emergengy Cty Hosp Craiova, Reg Ctr Med Genet Dolj, Craiova 200642, Romania
[5] Cty Clin Emergency Hosp Craiova, Dept Cardiol, Craiova 200642, Romania
关键词
obesity; FGF21; myocardial infarction; GROWTH-FACTOR; 21; KIDNEY-DISEASE; URIC-ACID; EXPRESSION; IDENTIFICATION; ANTIOXIDANT; FACTOR-21; SYSTEM;
D O I
10.3390/cimb46080501
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fibroblast growth factor 21 (FGF21) is a hormone involved in regulating the metabolism, energy balance, and glucose homeostasis, with new studies demonstrating its beneficial effects on the heart. This study investigated the relationship between FGF21 levels and clinical, biochemical, and echocardiographic parameters in patients with acute coronary syndromes (ACSs). This study included 80 patients diagnosed with ACS between May and July 2023, categorized into four groups based on body mass index (BMI): Group 1 (BMI 18.5-24.9 kg/m2), Group 2 (BMI 25-29.9 kg/m2), Group 3 (BMI 30-34.9 kg/m2), and Group 4 (BMI >= 35 kg/m2). Serum FGF21 levels were measured by ELISA (Abclonal Catalog NO.: RK00084). Serum FGF21 levels were quantifiable in 55 samples (mean +/- SD: 342.42 +/- 430.17 pg/mL). Group-specific mean FGF21 levels were 238.98 pg/mL +/- SD in Group 1 (n = 14), 296.78 pg/mL +/- SD in Group 2 (n = 13), 373.77 pg/mL +/- SD in Group 3 (n = 12), and 449.94 pg/mL +/- SD in Group 4 (n = 16), with no statistically significant differences between groups (p = 0.47). Based on ACS diagnoses, mean FGF21 levels were 245.72 pg/mL for STEMI (n = 21), 257.89 pg/mL for NSTEMI (n = 9), and 456.28 pg/mL for unstable angina (n = 25), with no significant differences observed between these diagnostic categories. Significant correlations were identified between FGF21 levels and BMI, diastolic blood pressure, and serum chloride. Regression analyses revealed correlations with uric acid, chloride, and creatinine kinase MB. This study highlights the complex interplay between FGF21, BMI, and acute coronary syndromes. While no significant differences were found in FGF21 levels between the different BMI and ACS diagnostic groups, correlations with clinical and biochemical parameters suggest a multifaceted role of FGF21 in cardiovascular health. Further research with a larger sample size is warranted to elucidate these relationships.
引用
收藏
页码:8512 / 8525
页数:14
相关论文
共 52 条
  • [1] Impact of Obesity and Weight Loss on Cardiac Performance and Morphology in Adults
    Alpert, Martin A.
    Omran, Jad
    Mehra, Ankit
    Ardhanari, Sivakumar
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2014, 56 (04) : 391 - 400
  • [2] When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid
    Bagnati, M
    Perugini, C
    Cau, C
    Bordone, R
    Albano, E
    Bellomo, G
    [J]. BIOCHEMICAL JOURNAL, 1999, 340 : 143 - 152
  • [3] Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
    Barb, Diana
    Bril, Fernando
    Kalavalapalli, Srilaxmi
    Cusi, Kenneth
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08) : 3327 - 3336
  • [4] Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes
    Berti, Lucia
    Irmler, Martin
    Zdichavsky, Marty
    Meile, Tobias
    Boehm, Anja
    Stefan, Norbert
    Fritsche, Andreas
    Beckers, Johannes
    Koenigsrainer, Alfred
    Haering, Hans-Ulrich
    de Angelis, Martin Hrabe
    Staiger, Harald
    [J]. MOLECULAR METABOLISM, 2015, 4 (07): : 519 - 527
  • [5] Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome
    Bulnes, Juan Francisco
    Gonzalez, Leticia
    Velasquez, Leonardo
    Orellana, Maria Paz
    Venturelli, Paula Munoz
    Martinez, Gonzalo
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [6] Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris
    Cheng, Jing
    Su, Xing
    Qiao, Lei
    Zhai, Chungang
    Chen, Wenqiang
    [J]. BIOSCIENCE REPORTS, 2018, 38
  • [7] Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors
    Chow, Wing Sun
    Xu, Aimin
    Woo, Yu Cho
    Tso, Annette W. K.
    Cheung, Stephen C. W.
    Fong, Carol H. Y.
    Tse, Hung Fat
    Chau, Ming Tak
    Cheung, Bernard M. Y.
    Lam, Karen S. L.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (10) : 2454 - 2459
  • [8] Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?
    Crujeiras, A. B.
    Gomez-Arbelaez, D.
    Zulet, M. A.
    Carreira, M. C.
    Sajoux, I.
    de Luis, D.
    Castro, A. I.
    Baltar, J.
    Baamonde, I.
    Sueiro, A.
    Macias-Gonzalez, M.
    Bellido, D.
    Tinahones, F. J.
    Martinez, J. A.
    Casanueva, F. F.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2017, 41 (10) : 1570 - 1578
  • [9] Left-ventricular hypertrophy and obesity: a systematic review andmeta-analysis of echocardiographic studies
    Cuspidi, Cesare
    Rescaldani, Marta
    Sala, Carla
    Grassi, Guido
    [J]. JOURNAL OF HYPERTENSION, 2014, 32 (01) : 16 - 25
  • [10] Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
    Dushay, Jody
    Chui, Patricia C.
    Gopalakrishnan, Gosala S.
    Varela-Rey, Marta
    Crawley, Meghan
    Fisher, Ffolliott M.
    Badman, Michael K.
    Martinez-Chantar, Maria L.
    Maratos-Flier, Eleftheria
    [J]. GASTROENTEROLOGY, 2010, 139 (02) : 456 - 463